1155 results about "Chronic hepatitis" patented technology

The invention provides a monoclonal antibody against GP73 protein, a preparation method and an application thereof. The invention also provides an immunological quantitative detection kit for detecting GP73 in a PBLs sample and a preparation method thereof. The kit in the invention can be used for monitoring the development level of chronic hepatitis and prognosis, and can be used for early diagnosis of liver cancer. By using the kit in the invention to monitor the expression level of the GP73, the prognosis level and probability to cause cirrhosis and liver cancer can be determined for patients, and the most direct support is provided for preventing, diagnosing and curing liver cancer and hepatitis.

The invention relates to a diagnosing reagent for hepatitis B, disclosing detection grains for e antigens of the hepatitis B virus, which are of the luminous grains coated by anti-HBE antibodies. The invention also discloses preparation and application for the detection grains for e antigens of the hepatitis B virus; moreover, the invention further discloses an outside-body diagnosis reagent box for detecting e antigens of the hepatitis B in a blood serum sample of human beings as well as a method for utilizing the light excitation chemiluminescence principle to quantitatively and qualitatively detect e antigens of the hepatitis B virus. The reagent box of the invention can be jointly used to diagnose the individual acute or chronic hepatitis B together with other blood serums and clinic information, and screen the hepatitis B for women in the perinatal period so as to judge the risk of newborn babies contaminating the hepatitis B.

Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and / or treatment or prevention of HCV infection.

The invention discloses a new traditional Chinese medicine composition for treating chronic hepatitis and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following Chinese medicinal herbs of dried orange peel, rhizoma cyperi, pericarpium citri reticulatae viride, radix scrophulariae, root of rehmannia, folium isatidis, root of kudzu vine, houttuynia cordata, indigo naturalis, peach kernel, red flower, radix paeoniae alba, Tuckahoe, rhizoma alismatis, oriental wormwood, desmodium, polygonum cuspidatum, root of red-rooted salvia, radix bupleuri, angelica sinensis, herba lycopi, earthworm, goldthread, felwort and root bark of the peony tree. The traditional Chinese medicine composition can be prepared into a common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can remarkably improve the symptoms of mild acratia, inappetence, abdominal distension, pain over the liver and the like of chronic persisting hepatitis, and can improve the symptoms of asthenia, poor appetite, abdominal distension, semiliquid, pain over the liver, poor complexion, poorer health, manpower reduction, hepatomegaly accompanied with haphalgesia and rap pain, and splenomegaly of the chronic active hepatitis and the symptoms of jaundice, spider angioma, liver palms, acne and the like caused by the chronic hepatitis. The invention can also improve the symptoms of long-term obvious dysfunction of liver, ALT continuous increase or repeated fluctuation, albumin reduction, globulin increase, gamma globulin or IgG increase, time extension of protrombin time, capability of positive reaction in self antibody and rheumatoid factors, capability of circulating immune complex increase, capability of addiments C3 and C4 reduction and the like, and has accurate remarkable clinical treatment effect and rapid effect taking.

The invention discloses an FXR receptor modulator, and a preparation method and an application thereof, belonging to the field of medicinal chemistry. The FXR receptor modulator with a structure characteristic as shown in a formula I in the specification or pharmaceutically-acceptable salts or stereoisomers or solvates or prodrugs thereof can bind with an FXR (i.e., NR1H4) receptor and is used as an agonist or a partial agonist of the FXR receptor, thereby being able to be applied to prevention and treatment of FXR mediated diseases, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, or chronic hepatitis B, or gallstone, or liver cancer, or colon cancer, or inflammatory bowel diseases, etc., wherein a part of compounds specifically can reach an FXR-excited EC<50> of 100 nM or below, show good FXR agonist activity, have excellent application prospects, and provide a new medicine choice for clinical treatment of the FXR mediated diseases.

The present invention pertains to a composition comprising Ibogaine, an indole alkaloid, its active salts and its principal metabolite noribogaine, a demethylated form of ibogaine, for the treatment of hepatitis C and hepatitis C related complications, administered in single or multiple dose regimens effective to reduce somatic complaints, liver enzyme values and viral load caused by chronic hepatitis C in patients, and methods of using the same.

A compound Adefovir Dipivoxil (AD) in the form of anhydrous crystal for curing chronic hepatitis B is disclosed. It is just 9-[2-[bis(neopentanoyloxy methoxy)phosphorylmethoxy]ethyl] adenine. Its features are its high stability to light, moisture and heat. Its preparing process is also disclosed.

The present invention discloses a drug 'Jinling Xiaoyan Oral Liquor' made up by using 23 Chinese medicinal materials of toosendan fruit, corydalis tuber, codonopsis root, atractylodes root, white poria and others. It can be used for effectively curing acute and chronic gastritis, peptic ulcer, acute and chronic hepatitis, chelecystitis and pancreatis, etc. and its therapeutic effect is reliable.

Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and / or treatment or prevention of HCV infection.

The invention belongs to the technical field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition for treating acute and chronic hepatitis B and a preparation method thereof. The traditional Chinese medicine composition for treating acute and chronic hepatitis B is prepared from the following active pharmaceutical ingredients: 60g of oriental wormwood, 60g of herba oldenlandiae, 60g of radix salviae miltiorrhizae, 45g of lysimachia, 45g of rhizoma alismatis, 45g of red paeoniam 36g of Baikal skullcap root, 36g of radix bupleuri, 30g of wrinkled gianthyssop, 30g of green tangerine orange peel, 30g of dried orange peel, 30g of giant knotweed, 50g of radix isatidis, 50g of taraxacum, 50g of asket fern, 50g of fleece-flower root, 50g of glabrous greenbrier rhizome, 50g of radix paeoniae alba, 50g of rhizoma atractylodis macrocephalae, 50g of angelica, 50g of radix astragali, 50g of charred hawthorn, 50g of medicated leaven, 50g of stringy stonecrop, 36g of rhubarb, 50g of lucid ganoderma, 56g of radix curcumae, 36g of rhizoma cyperi, 60g of schisandra fruit, 36g of dark plum, 48g of kuh-seng, 36g of costus root and 36g of gardenia. The invention has the advantages of scientific formula, fine prescription, excellent medicine, no rare or strong inhibited item, fixed prescription, high safety and reliability, quick effect taking and high curative effect; the traditional Chinese medicine composition is concentrated into pills, and thus, is convenient for preparation and taking; and the traditional Chinese medicine composition is convenient for people and beneficial to people, and can treat both the symptoms and root causes without relapse.

A method of treating chronic hepatitis B is disclosed that comprises administering a T cell-stimulating amount of a vaccine to a patient. The vaccine comprises an immunogenic amount of chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (core) protein (HBc) that is engineered for both enhanced stability of self-assembled particles and the substantial absence of nucleic acid binding by those particles. The chimeric protein molecule can include one or more immunogenic epitopes peptide-bonded to one or more of the N-terminus, the immunogenic loop or the C-terminus of HBc. The enhanced stability of self-assembled particles is obtained by the presence of at least one heterologous cysteine residue near one or both of the amino-terminus and carboxy-terminus of the chimer molecule.

The invention relates to a liver cancer diagnostic marker composed of blood plasma microRNA (micro ribonucleic acid), a kit containing the marker and a new method for diagnosing liver cancer (in particular early liver cancer). The liver cancer diagnostic marker is composed of a plurality of nucleic acid molecules, wherein each nucleic acid molecule is used for coding at least one microRNA sequence; and preferably, the liver cancer diagnostic marker is composed of nucleic acid molecules for coding hsa-miR-122, hsa-miR-192, hsa-miR-21, hsa-miR-223, hsa-miR-26a, hsa-miR-27a, hsa-miR-801 and hsa-miR-1228. The kit can be applied to diagnosing hepatocellular carcinoma, in particular early hepatocellular carcinoma, or to differentiating the blood plasma of at least one hepatocellular carcinoma sufferer from the blood plasma of at least one healthy individual, and the blood plasma of at least one chronic hepatitis b sufferer or the blood plasma of at least one cirrhosis sufferer.

The present invention provides a pharmaceutical composition for treating chronic hepatitis C characterized by comprising at least one active ingredient selected from the group consisting of IL-15, myeloid dendritic cell maturation stimulators (for example, CpG oligo deoxynucleotide, GM-CSF, IL-4, LPS, CD40L, polyI:C, TNF-a and IFN-?) and lectin-binding substances (for example, mannose carbohydrate, fucose carbohydrate and anti-lectin antibody); and a method of treating chronic hepatitis C by using such active ingredient(s). In the above pharmaceutical composition and therapeutic method, it is possible to use INF-a together with these active ingredients.

Methods and kits for determining predisposition of an individual to develop fast progression rate of liver fibrosis are provided. Also provided are agents and pharmaceutical compositions useful in preventing fast progression of liver fibrosis and a method of identifying drug molecules which accelerate or induce liver fibrosis.

The invention discloses a beef ball which comprises main materials and auxiliary materials, wherein the main materials comprise the following components in parts by weight: 20-30 parts of beef, 2-4 parts of starch, 4-6 parts of soy isolate protein, 10-12 parts of icy water, 3-5 parts of chicken breast meat and 1-2 parts of egg liquid; the auxiliary materials are added according to the percentage of the weight of the main materials; the auxiliary materials comprise the following components in percentage by weight of the main materials: 0.5-2% of salt, 1-2.5% of sugar, 0.2-0.6% of aginomoto, 1-1.5% of fried shallot, 0.05-0.1% of beef flavor, 2-3% of soybean sauce and 1-2% of lycium barbarum. The beef ball is rich in nutrition and rich in protein, vitamin and microelement; the nutrient components of the livestock and poultry meat complement with one another; the skin is soft, crispy, very chewable, thick in fragrance and fragrant, tender and tasty; due to the adoption of lycium barbarum, the beef ball has the functions of nourishing the kidney and strengthening the essence, nourishing the liver to brighten the eye and moistening lung to arrest cough, and has a good tonifying function for people with blood and qi deficiency, weak constitution, vision diminution, anemia, chronic hepatitis, toxic or metabolism liver diseases and biliary system diseases.

The invention relates to hepatitis B diagnosis reagent, which discloses surface antibody testing fine particles for hepatitis B, which are luminous fine particles for coating surface antibody of hepatitis B. The invention also discloses a preparation and an application for the surface antibody testing fine particles for hepatitis B. In addition, the invention further discloses an in vitro diagnosis kit for measuring the surface antibody of hepatitis B and simultaneously discloses a method for using the kit. The kit can be used jointly with other blood serum and clinical information to diagnose the condition of acute or chronic hepatitis B infection of an individual, and can also be used for sieving hepatitis B of females in the perinatal period, so as to judge the danger of hepatitis B infection of newly born babies.

The invention discloses a spleen extract prepared from mammalsí» spleens through fat-removing, homogenating, comminuting, settling and hyperfiltrating, and comprises the following constituents: polypeptides, free amino acid, nucleic acid and total sugar. The spleen extract can be used for preparing medicament for the treatment of cell immunodeficiency diseases, respiratory tract and lung infection, chronic hepatitis B, mumps, aphtae, leucopenia, leukemia, regenerative anemia, and malignant tumour.

The invention relates to a herbal prescription for treating the liver (gallbladder) inflammation in the traditional Chinese medicine preparation field. The technique proposal is that: the invention includes materials with parts by following weights: eight to twelve parts of bupleurum, twelve to fifteen parts of each of white peony root (stir-fried), hovenia dulcis, immature orange fruit, endothelium corneum gigeriae, nutgrass galingale rhizome, turmeric root tuber, ginseng root, prunella, Chinese angelica and absinthin, ten to twelve parts of giant knotweed rhizome, and three to five parts of liquorice. The invention has effects of relieving liver Qi stagnation and stagnation eliminating and blood stasis removing. The effective rate and the cure rate of the invention for treating the chronic hepatitis, hepatocirrhosis, chronic cholecystitis, cholelithiasis and pathological changes such as pain in chest and hypochondrium caused by liver Qi stagnation and Qi stagnation and blood stasis are respectively ninety two percent and eighty seven percent.

The present invention discloses a health-care tea with the functions of supplementing vacuity, boosting qi, nourishing blood and regulating the function of the stomach. Said health-care tea is mainly made up by using ginseng, jujub and fresh ginger according to a certain weight ratio. Besides, it also has a certain auxiliary therapeutic effect for chronic diseases of chronic hepatitis and anemia, etc.

The present invention provides one new kind of glycyrrhetic acid derivative with high water solubility, high absorption, no irritation to blood vessel and capacity of being prepared into injection, and its preparation process, medicinal composition and preparation. The glycyrrhetic acid derivative has excellent treating effect on acute and chronic hepatitis, bacterial hepatitis, viral hepatitis, cerebral ischemia / re-perfusion damage, brain injury and myocardial ischemia / re-perfusion damage.

The present invention relates to a novel tissue culture system that provides for the long term culture of proliferating hepatocytes that retain hepatic function. Disclosed are methods and compositions for ex vivo culturing of hepatocytes and nonparenchymal cells on a matrix coated with a molecule that promotes cell adhesion, proliferation or survival, in the presence of growth factors, resulting in a long-term culture of proliferating hepatocytes that retain hepatic function. The co-culturing method results in the formation of matrix / hepatic cell clusters that may be mixed with a second structured or scaffold matrix that provides a three-dimensional structural support to form structures analogous to liver tissue counterparts. The hepatic cell culture system can be used to form bio-artificial livers through which a subjects blood is perfused. Alternatively, the novel hepatic cell culture system may be implanted into the body of a recipient host having a hepatic disorder. Such hepatic disorders, include, for example, cirrhosis of the liver, induced hepatitis, chronic hepatitis, primary sclerosing cholangitis and alpha1 antitrypsin deficiency.

The invention discloses new applications of an antibody of GDF15 (Growth differentiation factor 15) protein. The invention provides the following three applications of the antibody of the GDF15 protein: 1. the application in preparing a reagent for assisting to identify a hepatitis C patient or a hepatitis B patient; 2. the application in preparing a reagent kit for assisting to identify the hepatitis C patient or the hepatitis B patient; and 3. the application in preparing a reagent kit for assisting to identify the hepatitis C progress of the hepatitis C patient, wherein the hepatitis C progress is chronic hepatitis C, hepatitis C cirrhosis or liver cancer. On the basis of the three applications, the antibody of the GDF15 protein can be prepared into three reagent kits. The reagent kit can be used for the serological diagnosis of viral hepatitis (the hepatitis C or the hepatitis B) and judging the disease progress (the chronic hepatitis C, the hepatitis C cirrhosis or the liver cancer) and for prognosis and viral hepatitis treatment monitoring and has great value for the diagnosis and the treatment of the hepatitis C and the hepatitis B.

The invention relates to a traditional Chinese medicine preparation for treating chronic hepatitis b, which comprises the following raw medicines: angelica sinensis, oldenlandia diffusa, astragali, houttuynia, radix bupleuri, tropaeolum, baical skullcap, forsythia, isatis, self-heal, honeysuckle, magnolia vine fruit, tuckahoe, white atractylodes rhizome, prepared fleece-flower root, glossy privet fruit, yerbadetajo, root of red rooted salvia, white peony root, oriental wormwood, natural indigo, barbat skullcap, phellodendron bark, rhizoma cyperi, liquorice and cortex dictamni radicis. The traditional Chinese medicine preparation has the efficacies of soothing the liver, regulating the flow of qi, relieving the depressed liver, promoting blood circulation, removing blood stasis, invigorating qi, restoring qi, strengthening the body resistance, consolidating the constitution, and tonifying the liver and kidney. The traditional Chinese medicine preparation has the following beneficial effects of: 1, clearing away heat and toxic material, promoting urination and elimination of toxicant, removing heat from the liver, gall and liver, promoting blood circulation, removing blood stasis, strengthening the spleen and removing dampness by diuresis; 2, protecting liver, reducing enzyme, removing toxin, restoring the liver function to normal, and thoroughly removing virus; and 3, nourishing after birth, enhancing the body immunologic function, and promoting hepatocyte proliferation. All medicines have synergistic effects to restore the body immunologic function to normal and achieve the purposes of removing virus and promoting recovery.

The present invention is directed to a molecule comprising a polypeptide having substantial homology with a CTL epitope selected from the group consisting of ADLMGYIPLV (Core131-140; SEQ ID NO:1), LLALLSCLTV (Core178-187; SEQ ID NO:2), QLRRHIDLLV (SEQ ID NO:55), LLCPAGHAV (NS31169-1177; SEQ ID NO:26), KLVALGINAV (NS31406-1415; SEQ ID NO:28), SLMAFTAAV (NS41789-1797; SEQ ID NO:34), LLFNILGGWV (NS41807-1816; SEQ ID NO:35), and ILDSFDPLV (NS52252-2260; SEQ ID NO:42). Such molecules are used for the treatment and prevention of acute or chronic HCV hepatitis; suitable pharmaceutical compositions and methods using such compositions are disclosed.

A Chinese medicine in the form of coated tablets for treating liver cancer, hepatocirrhosis, hepatitides, breast cancer, etc is prepared from 21 Chinese-medicinal materials including pilose asiabell root, ground beetle, coix seed, peach kernel, etc. Its preparing process is also disclosed.

The invention discloses a medicine for treating chronic hepatitis B, which contains the raw materials by the mixture ratio: 6-18% of herba artemisiae capillaries, 1-7% of Chinese thorowax, 1-7% of angelica, 3-12% of radix paeoniae alba, 3-12% of salvia miltiorrhiza, 1-10% of radix curcumae, 1-7% of rhizoma corydalis, 1-7% of common burreed rhizome, 1-7% of rhizoma zedoariae, 1-7% of nutgrass galingale rhizome, 1-7% of fructus meliae toosendan, 1-10% of dangshen, 1-7% of largehead atractylodes rhizome, 6-18% of radix astragali, 3-12% of indian bread, 1-7% of immature bitter orange, 1-7% of amomum villosum, 1-7% of areca, 0.5-5% of Chinese eaglewood and 1-7% of liquorice; the medicine is prepared by adopting conventional method. The medicine has the efficacies of clearing heat and promoting diuresis, nourishing the liver and invigorating the spleen, regulating the flow of qi and removing blood stasis, and can be used for treating chronic hepatitis B with remarkable effects, short period of treatment and rapid effects.

The present invention relates to the general field of recombinant protein expression, purification of recombinant proteins, diagnosis of HCV infection, prophylactic treatment against HCV infection and to the prognosing / monitoring of the clinical efficiency of treatment of an individual with chronic hepatitis, or the prognosing / monitoring of the natural disease. In particular, the present invention relates to the use of yeast, i.e. Hansenula or Saccharomyces glycosylation minus strains, for the efficient expression of HCV envelope proteins that are core-glycosylated, purification methods for these proteins, and the use in various applications, such as the use in diagnosis, prophylaxis or therapy of HCV envelope proteins purified according to the present invention.

The present invention relates to a method for treating a fatty liver disease or disorder in a patient in need thereof. The method comprises administering at least one matrix metalloproteinase (“MMP”) inhibitor to the patient. Fatty liver disease or disorders include, for example, NAFLD, NASH, ALD, fatty liver associated with chronic hepatitis infection, TPN, steroid treatment, tamoxifen treatment, gastrointestional operations, diabetes and Reye's Syndrome. The method is particularly useful when the fatty liver disease is associated with TPN and the patient is an infant or when the patient is obese. MMP inhibitors useful in the present invention include, for example, Marimastat, tetracyclines, Prinomastat, Batimastat, BAY 12-9566, AG3340, BMS-275291, Neovastat, BB-3644, KB-R7785, TIMP1, TIMP2, doxycycline, minocycline, RS-130,830; CGS 27023A, Solimastat, Ro 32-3555, BMS-272591, and D2163. Marimastat is a preferred MMP inhibitor.

The invention relates to bio-pharmaceutical engineer technology domain. At present, the therapeutic drugs for HBV infection mainly depend on IFN-Alpha and nucleotide analog, which can not kill virus thoroughly with worse remote therapeutic effect. The invention provides a cytotoxic T cell epitope vaccine for hepatitis B, comprising a fused polypeptide formed by connecting 21 CTL epitopes selected from CTL epitopes data of HBV antigen and two universal epitopes of auxiliary T lymphocyte. Saccharomyces Serevisiae is selected to express the fused antigen and mixes with immunologic adjvant. The said vaccine can activate and enhance the cellular immune response of patient with chronic HBV infection. The vaccine can also promote the immune elimination of HBV, and can be used for treatment of chronic hepatitis B.

The invention discloses a method for establishing a seroglycoid N-glycome atlas model of chronic hepatitis liver injury. The method comprises the following steps: detecting a seroglycoid N-glycome atlas by using a G-Test detection method, establishing an N-glycome atlas model with significant difference between liver injury patients and normal control personnel, and screening NG1A2F with significant expression difference between a liver injury group and a normal control group. Based on the N-glycome atlas model established by the method disclosed by the invention, the detection sensitivity andspecificity of liver injury respectively reach 80.0% and 74.4%. In subsequent applications, the degree of liver injury of personnel to be detected can be detected by comparing the peak values of single peak NG1A2F in the N-glycome atlas of the serum of the personnel to be detected and in the atlas model established by the method. Based on the method disclosed by the invention, a plurality of patients with chronic hepatitis liver injury can be subjected to routine and non-invasive detection to help doctors and the patients to monitor the occurrence and progression of the chronic hepatitis liver injury in time, and the method is expected to be promoted and used in clinical practice.